BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces the resignation of Gilles Avenard MD. as Board Member and Deputy Chief Executive Officer, in charge of R&D.
Pierre Attali MD., who has been serving BioAlliance Pharma as Chief Medical Officer for several years is today appointed Chief Operating Officer.
“I am delighted by Pierre Attali’s appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the Company and its commercial partners when preparing the next launches of BioAlliance’s products”, says Dominique Costantini, CEO of BioAlliance Phama. “On behalf of BioAlliance’s Teams and Board of Directors, I wish to sincerely thank Gilles Avenard for the creative spirit he succeeded to instill in the Company as founder and as manager, for his strong contribution and for the organization he put in place within the company. The innovations he brought to the Company throughout these years help us achieve key steps in its development. We truly wish him personal and professional success”.